<DOC>
	<DOCNO>NCT00834249</DOCNO>
	<brief_summary>The objective study compare rate extent absorption venlafaxine 25 mg tablet ( test ) versus Effexor® ( reference ) administer 1 x 25 mg tablet feed condition .</brief_summary>
	<brief_title>Venlafaxine 25 mg Tablets Under Non-Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>Subjects females and/or male , nonsmoker , 18 year age old . Female subject postmenopausal surgically sterilize . Postmenopausal status define absence menses past 12 month hysterectomy bilateral oophorectomy least 6 month ago . Sterile status define hysterectomy , bilateral oophorectomy tubal ligation least 6 month ago . Clinically significant illness within 4 week administration study medication . Clinically significant surgery within 4 week administration study medication . Any clinically significant abnormality find medical screening . Any reason , opinion medical subinvestigator , would prevent subject participate study . Abnormal laboratory test judge clinically significant . Positive urine drug screen screen . Positive test hepatitis B , hepatitis C , HIV screen . ECG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 mmHg ; heart rate less 50 100 bpm ) screening . Subjects BMI ≥ 30.0 . History significant alcohol abuse within six month screen visit indication regular use fourteen unit alcohol per week ( 1 Unit 150 mL wine 360 mL beer 45 mL alcohol 40 % ) . History drug abuse use illegal drug : use soft drug ( marijuana ) within 3 month screen visit hard drug ( cocaine , phencyclidine ( PCP ) crack ) within 1 year screen visit . History allergic reaction venlafaxine . History allergic reaction heparin . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , rifampin/rifabutin ; examples inhibitor : antidepressant , cimetidine , diltiazem , erythromycin , ketoconazole , MAO inhibitor , neuroleptic , verapamil , quinidine ) within 30 day prior administration study medication . Use investigational drug participation investigational study within 30 day prior administration study medication . History presence clinically significant gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , liver kidney disease condition know interfere absorption , distribution , metabolism excretion drug . Any history presence clinically significant neurological , endocrinal , cardiovascular , pulmonary , hematologic , immunologic , psychiatric metabolic disease . Use prescription medication within 14 day prior administration study medication overthecounter product ( include natural food supplement , vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption . Positive alcohol breath test screening . Subjects use tobacco form within 90 day precede study drug administration . Intolerance venipuncture . Subjects clinically significant history tuberculosis , epilepsy , asthma , diabetes , psychosis , glaucoma eligible study . Subjects unable understand unwilling sign Informed Consent Form . Any food allergy , intolerance , restriction special diet , opinion medical subinvestigator , contraindicate subject 's participation study . Subjects depot injection implant drug 3 month prior administration study medication . Donation plasma ( 500 mL ) within 7 Days . Donation loss whole blood prior administration study medication follow : less 300 mL whole blood within 30 day ; 300 mL 500 mL whole blood within 45 day ; 500 mL whole blood within 56 day . Subjects consume food beverage contain grapefruit ( e.g . fresh , can , frozen ) within 7 day prior administration study medication . Subjects know presence volumedepletion . Subjects predispose bleed skin mucous membrane . Subjects history know presence impaired platelet aggregation . Subjects history seizure . Breastfeeding subject . Positive urine pregnancy test screening ( performed female ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>